A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma
For more information about the trial above please contact the study team:
Principal Investigator, Hamza Hashmi, at firstname.lastname@example.org.
Study Coordinator, Sarah Britton, at email@example.com, or please call +1 843-792-8856.
Trial opened at the following institutions: Medical University of South Carolina